Highlights

  • Clever Culture (ASX:CC5) has secured orders for two additional APAS Independence instruments from Novo Nordisk.
  • The new units will support formal validation work at a Danish site and integration with Novo Nordisk’s laboratory information management infrastructure.
  • Eight global pharmaceutical manufacturers have installed APAS Independence, while Clever Culture continues to pursue opportunities across major drugmakers.
  • Further commercial expansion will depend on successful validation, additional customer deployments and improving recurring revenue.

A repeat order from a major global pharmaceutical company is an important commercial development for an emerging ASX technology business. On 7 September 2026, Adelaide-based Clever Culture Systems (ASX:CC5) announced that Novo Nordisk had ordered two additional APAS Independence instruments, lifting its installed base with the pharmaceutical group to three.

What was actually announced

The two instruments follow an approximately 12-month evaluation of the first unit Novo Nordisk purchased in July 2025, which was assessed by a centralised team in Denmark.

Both new machines are destined for a single Danish site, where they will undergo formal global validation supporting Good Manufacturing Practice requirements.

The order also includes customised software work to connect APAS with Novo Nordisk’s global Laboratory Information Management System. Such integration could make future deployment across additional locations more straightforward if the technology successfully progresses through validation.

Two caveats remain important. Clever Culture (ASX:CC5) did not disclose the dollar value of the order, stating only that pricing for each instrument was consistent with previously disclosed targeted pricing. The company also did not specify delivery or installation timing.

The transaction represents a confirmed purchase order rather than a framework agreement covering Novo Nordisk’s wider manufacturing network. Validation at one site therefore represents progress towards potential wider adoption rather than a commitment to broader deployment.

The machine, and why drugmakers care

APAS Independence automates part of the microbiology workflow used in pharmaceutical manufacturing.

Sterile production facilities conduct environmental monitoring by incubating culture plates to detect potential contamination. Traditionally, microbiologists visually inspect these plates.

APAS Independence uses artificial intelligence to screen plates, identify clear negatives and flag samples requiring further human review, while creating a standardised digital audit trail.

The system can process both 90mm settle plates and 55mm contact plates on a single instrument, a capability Clever Culture has positioned as a point of differentiation.

For pharmaceutical manufacturers, automation potentially offers greater consistency in microbiology workflows while reducing the amount of routine manual plate reading required.

The land-and-expand thesis

Clever Culture’s commercial strategy is based partly on customers initially adopting a limited number of instruments, validating the technology and potentially expanding deployments later.

AstraZeneca provides an example of this model, having progressed from an initial instrument to 12 installed units globally.

Eight global pharmaceutical manufacturers now have APAS Independence installed. As at June 2026, Clever Culture reported engagement with 14 of the world’s top 20 pharmaceutical companies and a pipeline exceeding 40 qualified opportunities.

Novo Nordisk is particularly relevant because of its substantial global manufacturing footprint. If validation in Denmark is completed successfully and the laboratory information management integration performs as intended, the operational pathway towards additional installations could become clearer.

However, broader deployment remains a potential outcome rather than an established commitment.

The financial reality

Clever Culture’s financial position highlights the importance of converting pharmaceutical engagement into sustained commercial sales.

For the year ended 30 June 2026, the company reported revenue of $4.67 million, down 29.6%, including $2.89 million from instrument sales and $1.23 million from annual licence, maintenance and support fees.

Clever Culture (ASX:CC5) recorded a net loss after tax of $2.24 million and ended the period with $1.7 million in cash.

The company also indicated that it expected at least $3.4 million of inflows over the following two quarters from receivables, R&D tax incentive claims and committed customer payments.

Revenue can remain uneven for a Business at this stage because individual instrument orders can materially influence reported sales from one period to another.

Management has also indicated expectations for a step-change in sales growth during FY27. Actual commercial performance will depend on the pace at which qualified opportunities progress into customer orders and installations.

What to watch

The first area to monitor is whether validation at the Danish site is successfully completed and whether that process leads to additional installations across Novo Nordisk’s wider network.

The second is the development of recurring software, licence, maintenance and support revenue. Growth in recurring income could help reduce some of the variability associated with instrument sales.

The third is cash generation. Investors will be watching whether expected customer payments, receivables and other anticipated inflows support the company’s operating requirements while commercial activity expands.

Clever Culture (ASX:CC5) has demonstrated that large pharmaceutical customers are willing to evaluate and, in some cases, expand their use of APAS Independence. The next commercial test is whether these individual deployments can develop into broader customer rollouts and a more predictable revenue base.